Table 3 Demographic and clinical data of diabetic subjects with and without PAD
From: Sortilin levels are associated with peripheral arterial disease in type 2 diabetic subjects
| Â | WPAD | PAD | P value |
|---|---|---|---|
(n = 80) | (n = 74) | ||
Male (%) | 69 | 65 | 0.34 |
Age (years ± SD) | 73.1 ± 6.4 | 69.8 ± 6.3 | 0.89 |
Body mass index (kg/m2) | 24.3 ± 2.1 | 23.9 ± 2.8 | 0.52 |
Smoking (current) (%) | 17 (21.25) | 19 (25.67) | 0.032 |
Hypertension (%) | 35 (44.0) | 47 (63.5) | 0.024 |
Coronary artery disease (%) | 25 (31.2) | 39 (52.7) | 0.031 |
Diabetes duration (years ± SD) | 10.1 ± 6.1 | 11.6 ± 5.9 | 0.97 |
Total cholesterol (mmol/L) | 5.97 (1.81) | 5.87 (1.35) | 0.78 |
HDL-cholesterol (mmol/L) | 1.24 (1.21) | 1.20 (1.21) | 0.67 |
LDL-cholesterol (mmol/L) | 2.82 (1.08) | 2.78 (0.83) | 0.73 |
Triglyceride (mmol/L) | 2.32 (1.67) | 1.98 (1.12) | 0.99 |
Fasting glucose (mmol/L) | 7.19 (1.12) | 7.61 (1.85) | 0.75 |
Glycated hemoglobin (%) | 7.13 (1.41) | 7.21 (1.84) | 0.59 |
eGFR (mL/min per 1.73Â m2) | 72.12 (8.19) | 67.98 (6.76 | 0.12 |
Aspartate aminotransferase (UI/L) | 38.2 (4.5) | 34.4 (3.8) | 0.61 |
Alanine aminotransferase (UI/L) | 41.1 (4.9) | 44.3 (3.9) | 0.45 |
Total bilirubin (mg/dL) | 0.9 (0.3) | 1.1 (0.4) | 0.33 |
Alkaline phosphatase (UI/L) | 109.6 (12.3) | 112.3 (9.4) | 0.56 |
Hemoglobin (g/dL) | 11.6 (2.12) | 12.1 (2.01) | 0.98 |
White blood cells (× 10E3/μL) | 5.9 (0.68) | 6.1 (0.98) | 0.85 |
Platelets (× 10E3/μL) | 254 (15.2) | 236 (17.3) | 0.52 |
Treatment | |||
 Diet only (%) | 9 (11.25) | 11 (14.86) | 0.76 |
 Oral agents (%) | 42 (52.5) | 38 (51.35) | 0.88 |
 Insulin therapy (%) | 38 (47.5) | 35 (47.29) | 0.65 |
PAD | |||
 1-Fontaine’s II (%) |  | 36 (48.64) |  |
 2-Fontaine’s III (%) |  | 24 (32.43) |  |
 2-Fontaine’s IV (%) |  | 14 (18.91) |  |